Related Experiment Video

Updated: May 8, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications

Fulvio Borella1, Stefano Fucina1, Ylenia Seminara1

  • 1Gynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Current Oncology (Toronto, Ont.)
|December 27, 2024
PubMed

Insights

Topoisomerase II alpha (TOP2A) is crucial for ovarian cancer cell growth. Targeting TOP2A offers a promising therapeutic strategy for epithelial ovarian cancer (EOC), potentially overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Topoisomerase II alpha (TOP2A) is vital for DNA replication and cell proliferation.
  • Overexpression of TOP2A in epithelial ovarian cancer (EOC) correlates with poor prognosis and treatment resistance.

Purpose of the Study:

  • To review the biological roles of TOP2A in EOC.
  • To discuss TOP2A as a therapeutic target for EOC management.

Main Methods:

  • Literature review of TOP2A's function in EOC.
  • Analysis of mechanisms driving tumor progression and recurrence.
  • Evaluation of clinical strategies targeting TOP2A.

Main Results:

  • TOP2A overexpression contributes to EOC progression and recurrence.
  • TOP2A inhibitors show potential in EOC treatment.
  • Combination therapies involving TOP2A inhibitors may enhance efficacy.

Conclusions:

  • Targeting TOP2A is a viable strategy for EOC therapy.
  • Further research into TOP2A inhibitors and combination treatments is warranted.
  • Understanding TOP2A's role is key to improving EOC patient outcomes.
Keywords:
PARPiTOP2Aanthracyclinesdoxorubicinetoposideimmune checkpoint inhibitorsovarian cancertopoisomerase

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...